Rebecca Aft, MD, PhD

Surgeon

Rebecca Aft

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Breast Disease

  • Breast Cancer

  • Oncology

  • General Surgery

Primary Academic Title

Professor of Surgery, Division of General Surgery, Section of Endocrine and Oncologic Surgery, WashU Medicine

Board Certification

  • 1998: American College of Surgeons, General Surgery

Training

  • 1978 - 1983: Predoctoral Fellow, Oncology, University of Wisconsin, Madison, WI
  • 1984 - 1987: Postdoctoral Fellow, Cell Biology, Weizmann Institute of Science, Rehovot, Israel
  • 1992 - 1995: Resident, Surgery, WashU Medicine, St. Louis, MO
  • 1995 - 1996: Senior Registrar, University of Sydney, Sydney, Australia
  • 1996 - 1997: Chief Resident, Surgery, WashU Medicine, St. Louis, MO

Education

  • 1992: MD, WashU Medicine, St. Louis, MO
  • 1983: PhD, Oncology, University of Wisconsin, Madison, WI

Research & Selected Publications

Research Interest

Glucose transporters in breast cancer; breast cancer and PET scanning.

Research Publications

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Aft R, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun | 2026

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Authors:

Gradishar WJ, Moran MS, Abraham J, one or more additional authors omitted Aft R, one or more additional authors omitted Kumar R

Journal & Year:

J Natl Compr Canc Netw | 2025

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
Authors:

Neven P, Stahl N, Vidal M, one or more additional authors omitted Aft R, one or more additional authors omitted Ciruelos E

Journal & Year:

Clin Cancer Res | 2024

Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages
Authors:

Iglesia MD, Jayasinghe RG, Chen S, one or more additional authors omitted Aft R, one or more additional authors omitted Ding L

Journal & Year:

Nat Cancer | 2024

Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Authors:

Gradishar WJ, Moran MS, Abraham J, one or more additional authors omitted Aft R, one or more additional authors omitted Kumar R

Journal & Year:

J Natl Compr Canc Netw | 2024

Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIME
Authors:

Phan TG, Weilbaecher KN, Aft R, Croucher PI , Chaffer CL

Journal & Year:

Cancer Discov | 2024

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Authors:

Batool SM, Yekula A, Khanna P, one or more additional authors omitted Aft R, one or more additional authors omitted Balaj L

Journal & Year:

Cell Rep Med | 2023